- Drugs
- Tuesday, 16 Jun 2020
Scientists hail dexamethasone as 'major breakthrough' in treating COVID-19
Results of trials announced on Tuesday showed dexamethasone, which is used to reduce inflammation in other diseases, reduced death rates by around a third among the most severely ill COVID-19 patients admitted to hospital.
The results suggest the drug should immediately become standard care in patients with severe cases of the pandemic disease, said the researchers who led the trials.
“This is a result that shows that if patients who have COVID-19 and are on ventilators or are on oxygen are given dexamethasone, it will save lives, and it will do so at a remarkably low cost,” said Martin Landray, an Oxford University professor co-leading the trial, known as the RECOVERY trial.
“It’s going to be very hard for any drug really to replace this, given that for less than 50 pounds ($63.26), you can treat eight patients and save a life,” he told reporters in an online briefing.
His co-lead investigator, Peter Horby, said dexamethasone was “the only drug that’s so far shown to reduce mortality - and it reduces it significantly.”
“It is a major breakthrough,” he said. “Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.”
There are currently no approved treatments or vaccines for COVID-19, the disease caused by the new coronavirus which has killed more than 431,000 globally.
Related Industry Updates
See how South Africa Anti-Infective Market is Changes during 2019-2027 with an increase in Revenue of $2572.5Mn| Sanofi, Abbott, Pfizer
Oct 27, 2020
Physiological Saline Market is expected to reach US$ 9,057.04 million by 2030
Dec 29, 2023
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
Jun 27, 2020
BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO
Jun 30, 2020
Alligator Bioscience Presents Promising Interim Phase I Data for its Bispecific Drug Candidate ATOR-1015 at AACR
Apr 27, 2020
UnitedHealth rises on 'minimal' COVID-19 impact on results & maintained its forecast
Apr 15, 2020
Europe Small Molecule Drug Delivery Market Opportunity Assessment and Forecast up to 2027
Sep 05, 2020